2013
DOI: 10.1038/ijo.2013.209
|View full text |Cite
|
Sign up to set email alerts
|

The small molecule indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity

Abstract: Objectives:Activation of the Wnt/β-catenin signaling pathway inhibits adipogenesis by maintaining preadipocytes in an undifferentiated state. We investigated the effect of indirubin-3′-oxime (I3O), which was screened as an activator of the Wnt/β-catenin signaling, on inhibiting the preadipocyte differentiation in vitro and in vivo.Methods:3T3L1 preadipocytes were differentiated with 0, 4 or 20 μM of I3O. The I3O effect on adipocyte differentiation was observed by Oil-red-O staining. Activation of Wnt/β-catenin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
31
0
1

Year Published

2015
2015
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 34 publications
(32 citation statements)
references
References 43 publications
0
31
0
1
Order By: Relevance
“…It is interesting to notice that different compounds with even modest structure changes may lead to quite different physiological effects. One recent research has suggested that indirubin-3′-oxime (I3O), which is a synthesized analog of indirubin, has potential to prevent obesity and metabolic syndrome by inhibiting the differentiation of preadipocytes into mature adipocytes [86]. In our study, we noted that treatment of brown adipocytes with I3O in vitro can only displayed a slight but no significant increase in the expression of BAT marker gene Ucp1 ( Supplymentary Figure 2A), suggest different mechanism involved in the regulation of UCP1 expression compared with indirubin.…”
Section: Discussionmentioning
confidence: 99%
“…It is interesting to notice that different compounds with even modest structure changes may lead to quite different physiological effects. One recent research has suggested that indirubin-3′-oxime (I3O), which is a synthesized analog of indirubin, has potential to prevent obesity and metabolic syndrome by inhibiting the differentiation of preadipocytes into mature adipocytes [86]. In our study, we noted that treatment of brown adipocytes with I3O in vitro can only displayed a slight but no significant increase in the expression of BAT marker gene Ucp1 ( Supplymentary Figure 2A), suggest different mechanism involved in the regulation of UCP1 expression compared with indirubin.…”
Section: Discussionmentioning
confidence: 99%
“…Although several FDA-approved anti-obesity drugs, including Orlistat, Belviq, and Qsymia, are currently available, their efficiencies remain insufficient (providing a mean weight loss of 3-10%), and they are associated with severe side effects, including birth defects, somnolence, and paraesthesia [25]. Drug development process is hard due to the complex nature of the obesity which is associated with metabolic problems, genetic abnormalities and lifestyle [26].…”
Section: Discussionmentioning
confidence: 99%
“…The activated Wnt/β-catenin pathway leads to an increase of β-catenin and a decrease of C/EBPα and PPARγ, the main transcriptional factors in adipogenesis. Therefore, Wnt signaling has been suggested as an attractive target for anti-obesity drugs [65]. Inhibition of PPARγ by an antagonist prevented high fat diet (HFD)-induced obesity and improved glucose and lipid metabolism [66].…”
Section: Discussionmentioning
confidence: 99%